Psoriatic arthritis and psoriasis: Need for a multidisciplinary approach

被引:23
作者
Qureshi, AA
Husni, ME
Mody, E
机构
[1] Harvard Univ, Sch Med, Dept Dermatol, Brigham & Womens Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Ctr Skin & Related Musculoskeletal Dis, Boston, MA USA
关键词
D O I
10.1016/j.sder.2005.01.006
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriatic arthritis is a progressive and often destructive form of seronegative inflammatory arthritis that is associated with psoriasis. It can be difficult to diagnose because it can present in a number of different ways, often indistinguishable from noninflammatory arthropathies such as osteoarthritis as well as inflammatory arthritis such as gout. Severe arthritis may be observed in the absence of psoriasis, or mild arthritis may be seen in the presence of moderate-to-severe psoriasis. A high index of suspicion, screening of psoriasis patients, and close follow-up and evaluation with rheumatology often is needed to make the diagnosis. Early recognition of the disorder and timely therapy can prevent long-term complications, such as permanent joint destruction and disability. With the advent of biologic agents, we are better equipped to manage psoriatic arthritis today. Because dermatologists are on the front-line of psoriasis management, we are perfectly poised to identify and help improve care for patients who suffer from both psoriasis and psoriatic arthritis. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:46 / 51
页数:6
相关论文
共 25 条
[1]   Etanercept in psoriatic arthritis [J].
Anandarajah, AP ;
Ritchlin, CT .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (01) :169-177
[2]   Role of novel biological therapies in psoriatic arthritis - Effects on joints and skin [J].
Braun, J ;
Sieper, J .
BIODRUGS, 2003, 17 (03) :187-199
[3]   Newly available treatments for psoriatic arthritis and their impact on skin psoriasis [J].
Galadari, H ;
Fuchs, B ;
Lebwohl, M .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (03) :231-237
[4]  
GLADMAN DD, 1990, J RHEUMATOL, V17, P809
[5]   Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis [J].
Goedkoop, AY ;
Kraan, MC ;
Teunissen, MBM ;
Picavet, DI ;
de Rie, MA ;
Bos, JD ;
Tak, PP .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (07) :769-773
[6]   Alefacept treatment in psoriatic arthritis - Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis [J].
Kraan, MC ;
van Kuijk, AWR ;
Dinant, HJ ;
Goedkoop, AY ;
Smeets, TJM ;
de Rie, MA ;
Dijkmans, BAC ;
Vaishnaw, AK ;
Bos, JD ;
Tak, PP .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2776-2784
[7]   Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis [J].
McKenna, SP ;
Doward, LC ;
Whalley, D ;
Tennant, A ;
Emery, P ;
Veale, DJ .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (02) :162-169
[8]   Recent advances in the management of psoriatic arthritis [J].
Mease, PJ .
CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (04) :366-370
[9]   HISTORICAL BACKGROUND AND EPIDEMIOLOGY [J].
ONEILL, T ;
SILMAN, AJ .
BAILLIERES CLINICAL RHEUMATOLOGY, 1994, 8 (02) :245-261
[10]   METHOTREXATE HEPATOTOXICITY IN PSORIASIS - CONSIDERATION OF LIVER BIOPSIES AT REGULAR INTERVALS [J].
ROBINSON, JK ;
BAUGHMAN, RD ;
AUERBACH, R ;
CIMIS, RJ .
ARCHIVES OF DERMATOLOGY, 1980, 116 (04) :413-415